US Patent

US11160795 — Methods of treating tuberous sclerosis complex with cannabidiol and everolimus

Method of Use · Assigned to GW Research Ltd · Expires 2041-03-01 · 15y remaining

Vulnerability score 45/100 Strong — defensible against typical IPR challenges

What this patent protects

This patent protects methods of treating tuberous sclerosis complex by administering cannabidiol and everolimus.

USPTO Abstract

The present disclosure provides methods of treating tuberous sclerosis complex comprising administering cannabidiol and everolimus.

Drugs covered by this patent

Epidiolex (CANNABIDIOL) · Jazz Pharms Res

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-3233`	—	Epidiolex

Patent Metadata

Patent number: US11160795
Jurisdiction: US
Classification: Method of Use
Expires: 2041-03-01
Drug substance claim: No
Drug product claim: No
Assignee: GW Research Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.